S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:OTIC

Otonomy Stock Forecast, Price & News

$2.05
-0.11 (-5.09%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$2.02
$2.11
50-Day Range
$1.63
$2.25
52-Week Range
$1.14
$6.98
Volume
99,460 shs
Average Volume
578,465 shs
Market Capitalization
$116.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.79
30 days | 90 days | 365 days | Advanced Chart
Receive OTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.


Otonomy logo

About Otonomy

Otonomy, Inc. operates as a biopharmaceutical company. It engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Headlines

-$0.17 EPS Expected for Otonomy, Inc. (NASDAQ:OTIC) This Quarter
November 24, 2021 |  americanbankingnews.com
Otonomy (NASDAQ:OTIC) Announces Quarterly Earnings Results
November 13, 2021 |  americanbankingnews.com
Otonomy (NASDAQ:OTIC) Stock Rating Reaffirmed by Cantor Fitzgerald
November 13, 2021 |  americanbankingnews.com
Otonomy (OTIC) to Release Earnings on Wednesday
November 5, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OTIC
Employees
56
Year Founded
N/A

Sales & Book Value

Annual Sales
$270 thousand
Book Value
$1.17 per share

Profitability

Net Income
$-44.73 million
Net Margins
-20,278.95%
Pretax Margin
-27,106.18%

Debt

Price-To-Earnings

Miscellaneous

Free Float
52,203,000
Market Cap
$116.20 million
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
11/28/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/10/2022

MarketRank

Overall MarketRank

2.06 out of 5 stars

Medical Sector

527th out of 1,391 stocks

Pharmaceutical Preparations Industry

246th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Otonomy (NASDAQ:OTIC) Frequently Asked Questions

Is Otonomy a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Otonomy stock.
View analyst ratings for Otonomy
or view top-rated stocks.

How has Otonomy's stock been impacted by Coronavirus?

Otonomy's stock was trading at $2.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OTIC shares have decreased by 21.8% and is now trading at $2.05.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Otonomy?

Otonomy saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 565,700 shares, an increase of 25.3% from the September 30th total of 451,600 shares. Based on an average trading volume of 346,600 shares, the days-to-cover ratio is presently 1.6 days. Currently, 1.1% of the shares of the company are short sold.
View Otonomy's Short Interest
.

When is Otonomy's next earnings date?

Otonomy is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Otonomy
.

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) posted its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). Otonomy had a negative trailing twelve-month return on equity of 72.42% and a negative net margin of 20,278.95%. During the same period in the prior year, the business earned ($0.22) EPS.
View Otonomy's earnings history
.

What price target have analysts set for OTIC?

2 analysts have issued 12 month target prices for Otonomy's shares. Their forecasts range from $5.50 to $6.00. On average, they expect Otonomy's share price to reach $5.75 in the next year. This suggests a possible upside of 180.5% from the stock's current price.
View analysts' price targets for Otonomy
or view top-rated stocks among Wall Street analysts.

Who are Otonomy's key executives?

Otonomy's management team includes the following people:
  • David A. Weber, President, Chief Executive Officer & Director
  • Paul E. Cayer, Chief Financial & Business Officer
  • Fabrice Piu, Vice President-Research & Preclinical Development
  • Robert Michael Savel, Chief Technical Officer
  • Alan C. Foster, Vice President-Research

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Who are Otonomy's major shareholders?

Otonomy's stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (2.88%), BlackRock Inc. (1.41%), Dimensional Fund Advisors LP (1.34%), Point72 Asset Management L.P. (1.14%), Renaissance Technologies LLC (1.07%) and Geode Capital Management LLC (0.80%).
View institutional ownership trends for Otonomy
.

Which institutional investors are selling Otonomy stock?

OTIC stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Two Sigma Advisers LP, Two Sigma Investments LP, Renaissance Technologies LLC, Squarepoint Ops LLC, and BlackRock Inc..
View insider buying and selling activity for Otonomy
or view top insider-selling stocks.

Which institutional investors are buying Otonomy stock?

OTIC stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Point72 Asset Management L.P., Two Sigma Securities LLC, Geode Capital Management LLC, and Barclays PLC.
View insider buying and selling activity for Otonomy
or or view top insider-buying stocks.

How do I buy shares of Otonomy?

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $2.05.

How much money does Otonomy make?

Otonomy has a market capitalization of $116.20 million and generates $270 thousand in revenue each year. The biopharmaceutical company earns $-44.73 million in net income (profit) each year or ($0.81) on an earnings per share basis.

How many employees does Otonomy have?

Otonomy employs 56 workers across the globe.

What is Otonomy's official website?

The official website for Otonomy is www.otonomy.com.

Where are Otonomy's headquarters?

Otonomy is headquartered at 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at [email protected], or via fax at 619-291-9190.


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.